The expression of RKIP, RhoGDI, galectin, c-Myc and p53 in gastrointestinal system of Cr(VI)-exposed rats

Journal of Applied Toxicology

Volumn 31, Issue 8, 2011, Pages 730-740

  Tsao, Der An ^a   Tseng, Wei Chang ^a   Chang, Huoy Rou ^b  

^a FOOYIN UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

Author keywords

C Myc; Chromium(VI); Galectin; P53; Raf kinase inhibitor protein (RKIP); Rho GDI

Indexed keywords

CHROMIUM DERIVATIVE; GALECTIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; HEXAVALENT CHROMIUM; MYC PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; COLON; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; GASTROINTESTINAL TRACT; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CHROMIUM; GALECTINS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; MALE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RATS, WISTAR; SPECTROPHOTOMETRY, ATOMIC; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS; RATTUS NORVEGICUS;

EID: 81455135562     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1621     Document Type: Article

References (41)

1. Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S. 2010. Implication of the galectin-3 in colorectal cancer development (about 325 Tunisian patients. Bull. Cancer 97(2): E1-8.
2. Baral A, Engelken RD. 2002. Chromium-based regulations and greening in metal finishing industries in the USA. Environ. Sci. Policy 5: 121-133.
3. Barceloux DG. 1999. Chromium. Clin. Toxicol. 37: 173-194.
4. Calcagno DQ, Leal MF, Assumpção PP, Smith MAC, Burbano RR. 2008. MYC and gastric adenocarcinoma carcinogenesis. World J. Gastroenterol. 14(39): 5962-5968.
5. Chatterjee D, Sabo E, Tavares R, Resnick MB. 2008. Inverse association between Raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin. Cancer Res. 14: 2994-3001.
6. Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY, Tseng CW, Lin LL, Chen JY, Wang MJ, Chen JH, Chen YJ. 2006. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J. Proteome Res. 5(10): 2727-2742.
7. Costa M. 1997. Toxicity and carcinogenicity of Cr(VI) in animal models and humans. Crit. Rev. Toxicol. 27(5): 431-442.
8. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. 2006. The c-Myc target gene network. Sem. Cancer Biol. 16: 253-264.
9. Danguy A, Camby I, Kiss R. 2002. Galectins and cancer. Biochim. Biophys. Acta 1572: 285-293.
10. Dayan AD, Paine AJ. 2001. Mechanisms of chromium toxicity, carcinogenicity and allergenicity: review of the literature from 1985 to 2000. Hum. Exp. Toxicol. 20(9): 439-451.
11. Fu Z, Smith PC, Zhang L. 2003. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl Cancer Inst. 95: 878-889.
12. Fu Z, Kitagawa Y, Shen R. 2006. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66: 248-256.
13. Golubovskaya VM, Cance W. 2010. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front. Biosci. 15: 901-912.
14. Hagan S, Al-Mulla F, Mallon E. 2005. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin. Cancer Res. 11: 7392-7397.
15. Harding MA, Theodorescu D. 2010. RhoGDI signaling provides targets for cancer therapy. Eur. J. Cancer 46(7): 1252-1259.
16. Isabelle C, Marie LM, Florence L, Robert K. 2006. Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R.
17. Keller ET, Fu Z, Yeung K. 2004. Brennan M. Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Lett. 207: 131-137.
18. Kerger BD, Finley BL, Corbett GE, Dodge DG, Paustenbach DJ. 1997. Ingestion of chromium(VI) in drinking water by human volunteers: absorption, distribution, and excretion of single and repeated doses. J. Toxicol. Environ. Hlth 50: 67-95.
19. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, Park SH, Chun KH. 2010. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138(3): 1035-1045.
20. Lazǎr D, Tǎban S, Sporea I, Dema A, Cornianu M, Lazǎr E, Goldiş A, Raţiu I, Vernic C. 2010. The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. Rom. J. Morphol. Embryol. 51(2): 249-257.
21. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. 2006. Loss of raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131: 1208-1217.
22. Malliri A, Collardy JG. 2003. Role of Rho-family proteins in cell adhesion and cancer. Curr. Opin. Cell Biol. 15: 583-589.
23. Melis R, White R. 1999. Characterization of colonic polyps by two-dimensional gel electrophoresis. Electrophoresis 20(4-5): 1055-1064.
24. Meyers JB. 1950. Acute pulmonary complications following inhalation of chromic acid mist. Ann. Ind. Hyg. Occup. Med. 2: 742-747.
25. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR. 2007. Loss of Raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am. J. Clin. Pathol. 127: 820-827.
26. Nardone G, Rippa E, Martin G, Rocco A, Siciliano RA, Fiengo A, Cacace G, Malorni A, Budillon G, Arcari P. 2007. Gastrokine 1 expression in patients with and without Helicobacter pylori infection. Dig. Liver Dis. 39(2): 122-129.
27. Oster SK, Ho CS, Soucie EL, Penn LZ. 2002. The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 84: 81-154.
28. Pitot HC, Hikita H, Dragan Y, Sargent L, Haas M. 2000. Review article: the stages of gastrointestinal carcinogenesis - application of rodent models to human disease. Aliment. Pharmacol. Ther. 14(suppl. 1): 153-160.
29. Rowbotham AL, Levy LS, Shuker LK. 2000. Chromium in the environment: an evaluation of exposure of the UK general population and possible adverse health effects. J. Toxicol. Environ. Hlth B Crit. Rev. 3(3): 145-178.
30. Salnikow K, Zhitkovich A. 2008. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem. Res. Toxicol. 21: 28-44.
31. Schuierer MM, Bataille F, Hagan S. 2004. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 64: 5186-5192.
32. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. 2006. Colorectal cancer: genetics of development and metastasis. J. Gastroenterol. 41(3): 185-192.
33. Tamura G. 2006. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J. Gastroenterol. 2(2): 192-198.
34. Tokino T, Nakamura Y. 2000. The role of p53-target genes in human cancer. Crit. Rev. Oncol. Hematol. 33: 1-6.
35. Tsao DA, Yu HS, Cheng JT, Ho CK, Chang HR. 2000. The change of beta-adrenergic system in lead-induced hypertension. Toxicol. Appl. Pharmacol. 164: 127-133.
36. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. 2008. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem. Pharmacol. 75: 405-413.
37. Weiderpass E, Vainio H, Kauppinen T, Vasama-Neuvonen K, Partanen T, Pukkala E. 2003. Occupational exposures and gastrointestinal cancers among Finnish women. J. Occup. Environ. Med. 45(3): 305-315.
38. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401(6749): 173-177.
39. Yeung K, Janosch P, McFenan B, Rose DW, Mischak H, Scdivy JM. 2000. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell. Biol. 20(9): 3079-3085.
40. Zhang L, Fu Z, Binkley C, Giordano T, Burant CF, Logsdon CD, Simeone DM. 2004. Raf kinase inhibitory protein inhibits β-cell proliferation. Surgery 136: 708-715.
41. Zhitkovich A. 2002. Chromium: exposure, toxicity and biomonitoring approaches. In Biomarkers of Environmentally Associated Disease: Technologies, Concepts, and Perspectives, Wilson SH, Suk WA (eds). CRC Press: New York; 269-287.